Wells Fargo analyst Derek Archila lowered the firm’s price target on Nurix Therapeutics (NRIX) to $25 from $32 and keeps an Overweight rating on the shares. The firm views bexobrutideg as highly de-risked in CLL and thinks regulatory updates and initiation of pivotal trials are modest catalysts in 2025. With shares approaching 52-week lows, it offers an attractive entry point for long-term investors, Wells adds.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target lowered to $35 from $36 at Stifel
- Nurix Therapeutics: Strong Financials and Strategic Collaborations Support ‘Buy’ Rating
- Promising Developments and Strategic Partnerships Propel Nurix Therapeutics: A Buy Recommendation
- Nurix Therapeutics, Inc. Earnings Report: Is it a Beat?
- Nurix Therapeutics Q1 2025 Financial Highlights